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COCHRANE REVIEWS
Cochrane Collaborative Review Group on Peripheral Vascular Disease:
Review Abstracts
Introduction Abstracts
The following abstracts are part of an ongoing series Abstract: Elastic compression stockings for the pre-
vention of deep vein thrombosisof articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases, which S. Amaragiri and T. A. Lees
Date of most recent substantive amendment: 8 Novemberis part of the Cochrane Collaboration. The reviews are
published in full on ‘The Cochrane Library’, a quarterly 1999
electronic journal available on CD-ROM, the Internet
and many Health Care Libraries. The electronic format
allows Cochrane reviews to accommodate new data Background
as they become available, making the library a con-
sistently up-to-date source of information over time. One of the settings in which deep vein thrombosis
(DVT) in the lower limb and pelvic veins occurs is
The abstracts appearing on the Cochrane Library prolonged immobilisation in hospital for various sur-
are now presented in a different, simpler, less scientific gical and medical illnesses. Use of graduated com-
format than the abstracts presented here to permit pression stockings (GCS) in these patients has been
greater accessibility to the public. However, the sub- proposed to decrease the risk of DVT.
stance of both versions is the same. Review abstracts
on Cochrane reviews are now indexed on MEDLINE.
Objectives
If you are interested in writing a Cochrane review
or contributing to the activities of the Cochrane Peri- The objective of this review was to determine the
pheral Vascular Diseases Group, please contact: magnitude of effectiveness of graduated compression
stockings in preventing deep vein thrombosis in vari-
Professor FGR Fowkes ous groups of hospitalised patients.
Cochrane Collaborative Review Group on Peri-
pheral Vascular Disease
Department of Community Health Sciences Search Strategy
Public Health Sciences
University of Edinburgh The reviewers searched the Cochrane Peripheral Vas-
Teviot Place cular Disease Group trials register, MEDLINE, and
Edinburgh EH8 9AG, U.K. EMBASE and hand searched Indexes Medicus. Various
Tel. +44 (0) 131 650 3220 GCS manufacturing companies and the principal in-
Fax. +44 (0) 131 650 6904 vestigators in the ongoing trials were contacted.
Any comments or criticisms on these Cochrane re-
views/abstracts should be made through the com- Selection Criteriaments/criticisms facility on the Cochrane Library, or
by contacting the group at the above address. Randomised controlled trials involving:
• Graduated compression stockings alone.
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• Graduated compression stockings used on a back- Abstract: Vitamin K antagonists or low molecular
weight heparin for the long-term treatment of symp-ground of any other DVT prophylactic method.
tomatic venous thromboembolism
J. F. van der Heijden, B. A. Hutten, H. R. Buller and
M. H. Prins
Data Collection and Analysis Date of most recent substantive amendment: 28 March
2000
One reviewer extracted the data, assessed the quality
of trials and analysed the results (SVA). This was
cross-checked and authenticated by the other reviewer
(TAL).
Background
Patients who have had an episode of symptomatic
Main Results venous thromboembolism are usually treated for at
least 5 days with intravenous unfractionated heparin
A total of 16 randomised controlled trials were iden- or subcutaneous low molecular weight heparin. There-
tified. Graduated compression stockings were applied after, they received a 3-month course of a vitamin
on the day before surgery or on the day of surgery K antagonist, with a dose adjusted to achieve an
and were worn up until discharge or until the patients International Normalized Ratio between 2.0 and 3.0.
were fully mobile. In the majority of the included Some patients have contraindications to vitamin K
studies, DVT was identified by radioactive I 125 uptake antagonists. In addition, treatment with vitamin K
test. antagonists has the disadvantage of regular laboratory
measurements.
Graduated compression stockings alone
Nine randomised controlled trials were identified in Objectives
this group. In the treatment group (GCS) of 624
patients, 81 developed DVT (13%) in comparison to The objective of this review was to evaluate the efficacy
the control group of 581 patients, where 154 (27%) and safety of long-term treatment of symptomatic
developed DVT, Peto’s odds ratio 0.34 (95% confidence venous thromboembolism with low molecular weight
interval 0.25, 0.46) favouring treatment with GCS. heparins compared with vitamin K antagonists.
GCS on a background of another prophylactic method
Search Strategy
Seven randomised controlled trials were identified in
this group. In the treatment group (GCS+another Computerised searches of MEDLINE, EMBASE and
method) of 501 patients, 10 (2%) developed DVT Current Contents were made and relevant journals
whereas in the control group of 505 patients, 74 (15%) were hand-searched using the search strategy de-
developed DVT, Peto’s odds ratio 0.24 (95% confidence scribed by the Cochrane Peripheral Vascular Disease
interval 0.15, 0.37). Group. In addition, randomised clinical trials were
located through personal communication with col-
leagues. Where necessary, the reviewers contacted
pharmaceutical companies for further information.Reviewers’ Conclusions
Analysis of these randomised controlled trials confirm
that GCS are effective in diminishing the risk of deep
vein thrombosis in hospitalised patients. Data ex- Selection Criteria
amination also suggests that GCS on a background of
another method of prophylaxis is even more effective Two reviewers evaluated studies independently for
methodological quality.than GCS alone.
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Data Collection and Analysis study from the analysis a statistically non-significant
reduction of the risk of recurrent symptomatic venous
Two reviewers reviewed and extracted data in- thromboembolism in favour of vitamin K antagonist
treatment remained (OR 1.95; 95% CI [0.74, 5.19]). Nodependently using a standard form.
Primary analysis concerned all patients in the studies differences in the risk of bleeding (OR 0.63; 95% CI
[0.21, 1.88]) and mortality (OR 1.13 ; 95% CI [0.47,during the period of randomised treatment. Additional
separate analyses were performed for category I and 2.69] were observed.
category II studies; studies that used similar initial
treatments in both study arms and those that used
different treatment regimes during the initial treat- Reviewers’ Conclusions
ment; and the total period of follow-up in the different
studies. Low molecular weight heparins are possibly as effect-
ive and safe as vitamin K antagonists in the prevention
of recurrent symptomatic venous thromboembolism
after an episode of symptomatic deep venous throm-
bosis, but have the disadvantage of much higher me-Main Results
dicinal costs. Treatment with low molecular weight
heparin is possibly a safe alternative in some patients:Five studies were identified that fulfilled our pre-
defined criteria (three category I and two category for example, patients who live in geographically in-
accessible places; patients who are reluctant to go toII studies). When all five studies were combined, a
statistically non-significant reduction of the risk of the thrombosis service on a regular basis; and patients
with contraindications to vitamin K antagonists (e.g.recurrent symptomatic venous thromboembolism in
favour of low molecular weight heparin treatment (OR pregnant women). Therefore, in the absence of defin-
itive evidence on the safety and efficacy of low mo-0.72; 95% CI [0.42, 1.23]) was found. In category I
studies, analysis of the pooled data showed a stat- lecular weight heparins compared with vitamin K
antagonists, we believe that treatment with vitaministically non-significant reduction of the risk of re-
current symptomatic venous thromboembolism in K antagonists is still the treatment of choice in the
prevention of recurrent symptomatic venous throm-favour of low molecular weight heparin treatment (OR
0.75; 95% CI [0.40, 1.39]). This OR was mainly due to boembolism after an episode of deep venous throm-
bosis, in the majority of patients.one possibly confounded study, and after omitting this
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